ASX:OPT Opthea (OPT) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Opthea Stock (ASX:OPT) 30 days 90 days 365 days Advanced Chart Get Opthea alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume504,572 shsAverage VolumeN/AMarket CapitalizationA$790.69 millionP/E RatioN/ADividend Yield0.24%Price TargetN/AConsensus RatingN/A Company Overview Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead product candidate is Sozinibercept (OPT 302), a soluble form of vascular endothelial growth factor receptor-3 VEGFR-3, currently under Phase 3 clinical development as a novel therapy for wet age-related macular degeneration and diabetic macular edema. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia. Read More Receive OPT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Opthea and its competitors with MarketBeat's FREE daily newsletter. Email Address OPT Stock News HeadlinesHealth Check: Opthea investors have $80m less to fight for after cash-burning quarterJuly 30, 2025 | msn.comRegal’s new global small caps fund on a tear, up 40pc in three monthsJuly 8, 2025 | afr.comAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Magnificent Seven—seven stocks he believes could deliver similar gains in under six years. His full breakdown is now live.August 13 at 2:00 AM | The Oxford Club (Ad)Opthea Limited Relocates Registered Office to MelbourneJuly 3, 2025 | tipranks.comASX slips; Opthea lifeline talks continue amid director exodusJune 1, 2025 | afr.comRegal says Platinum business a ‘melting ice cube’May 7, 2025 | afr.comOpthea, with shares still suspended, cuts workforce by 65% after drug trials cancelledApril 9, 2025 | msn.comRegal Partners shares slide on drop in funds under managementApril 8, 2025 | msn.comSee More Headlines OPT Stock Analysis - Frequently Asked Questions How were Opthea's earnings last quarter? Opthea Limited (ASX:OPT) announced its quarterly earnings data on Friday, August, 9th. The company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.09) by $0.00. Opthea had a positive trailing twelve-month return on equity of 543.34% and a negative net margin of 182,616.58%. What other stocks do shareholders of Opthea own? Based on aggregate information from My MarketBeat watchlists, some other companies that Opthea investors own include Skyworks Solutions (SWKS), Teladoc Health (TDOC), Vaxart (VXRT), Zion Oil & Gas (ZN), AST SpaceMobile (ASTS), Appian (APPN) and American Well (AMWL). Company Calendar Last Earnings8/09/2019Today8/13/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Biotechnology Sub-IndustryPharmaceutical Products Current SymbolASX:OPT CIKN/A Webwww.opthea.com Phone61 3 9826 0399FaxN/AEmployees8Year FoundedN/AProfitability EPS (Trailing Twelve Months)A($0.51) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-A$220.24 million Net Margins-182,616.58% Pretax MarginN/A Return on Equity543.34% Return on Assets-83.43% Debt Debt-to-Equity Ratio-186.85 Current Ratio2.94 Quick Ratio4.25 Sales & Book Value Annual SalesA$199.01 thousand Price / Sales0.00 Cash FlowN/A Price / Cash Flow10.29 Book ValueA($0.11) per share Price / BookN/AMiscellaneous Outstanding Shares1,230,000,000Free FloatN/AMarket CapA$790.69 million OptionableNot Optionable Beta1.61 The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (ASX:OPT) was last updated on 8/13/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCritical AI announcement set to ignite AI 2.0I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredNew Federal Land Rush About to Start?A $100 Trillion Wealth Shift Is Already Underway Lithium. Oil. Gold. Trillions in U.S. resources are being ...Stansberry Research | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Opthea Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Opthea With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.